1. Home
  2. INCY vs LAMR Comparison

INCY vs LAMR Comparison

Compare INCY & LAMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INCY
  • LAMR
  • Stock Information
  • Founded
  • INCY 1991
  • LAMR 1902
  • Country
  • INCY United States
  • LAMR United States
  • Employees
  • INCY N/A
  • LAMR N/A
  • Industry
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • LAMR Real Estate Investment Trusts
  • Sector
  • INCY Health Care
  • LAMR Real Estate
  • Exchange
  • INCY Nasdaq
  • LAMR Nasdaq
  • Market Cap
  • INCY 17.0B
  • LAMR 13.1B
  • IPO Year
  • INCY 1993
  • LAMR 1996
  • Fundamental
  • Price
  • INCY $105.55
  • LAMR $129.79
  • Analyst Decision
  • INCY Buy
  • LAMR Buy
  • Analyst Count
  • INCY 19
  • LAMR 4
  • Target Price
  • INCY $89.19
  • LAMR $131.75
  • AVG Volume (30 Days)
  • INCY 2.8M
  • LAMR 534.3K
  • Earning Date
  • INCY 10-28-2025
  • LAMR 11-06-2025
  • Dividend Yield
  • INCY N/A
  • LAMR 4.78%
  • EPS Growth
  • INCY 3878.02
  • LAMR N/A
  • EPS
  • INCY 5.90
  • LAMR 4.24
  • Revenue
  • INCY $4,813,105,000.00
  • LAMR $2,253,062,000.00
  • Revenue This Year
  • INCY $19.33
  • LAMR $4.38
  • Revenue Next Year
  • INCY $10.47
  • LAMR $3.72
  • P/E Ratio
  • INCY $17.64
  • LAMR $30.57
  • Revenue Growth
  • INCY 18.09
  • LAMR 2.98
  • 52 Week Low
  • INCY $53.56
  • LAMR $99.84
  • 52 Week High
  • INCY $109.28
  • LAMR $135.91
  • Technical
  • Relative Strength Index (RSI)
  • INCY 68.24
  • LAMR 68.05
  • Support Level
  • INCY $91.16
  • LAMR $124.41
  • Resistance Level
  • INCY $109.28
  • LAMR $130.55
  • Average True Range (ATR)
  • INCY 4.59
  • LAMR 3.14
  • MACD
  • INCY 0.49
  • LAMR 1.22
  • Stochastic Oscillator
  • INCY 80.28
  • LAMR 93.91

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About LAMR Lamar Advertising Company

Lamar Advertising Co is an outdoor advertising companies in the United States and operates as a Real Estate Investment Trust. It rent space for advertising on billboards, buses, shelters, benches, logo plates and in airport terminals and also offer customers a fully integrated service with all aspects of their display requirements from ad copy production to placement and maintenance. It has two operating segments: billboard and Others. Key revenue is generated from Billboard segment.

Share on Social Networks: